Contact
Please use this form to send email to PR contact of this press release:
Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
TO:
Please use this form to send email to PR contact of this press release:
Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
TO: